(Q28251617)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

prostate cancer screening

15 January 2020

main subject

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

2

Angela B Mariotto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Roman Gulati

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Shu Chen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ruth Etzioni

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

1 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Epidemiology

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1412-1417

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

15 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Mortality results from a randomized prostate-cancer screening trial

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Screening and prostate-cancer mortality in a randomized European study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Comorbidity and mortality results from a randomized prostate cancer screening trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Screening for prostate cancer: estimating the magnitude of overdetection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Estimating treatment benefits for the elderly: the effect of competing risks

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Asymptomatic incidence and duration of prostate cancer

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517213

Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival

27 November 2018

1 reference

12 December 2020

Screening and the number needed to treat

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

A population model of prostate cancer incidence

1 reference

12 December 2020

Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study

1 reference

12 December 2020

10.1016/J.JCLINEPI.2011.06.011

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22032753%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference